Antiphospholipid syndrome in pregnancy: A controlled treatment trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN55179279

Enrollment

Registered

2004-01-23

Start date

1998-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Interventions

1. Aspirin 2. Aspirin and low molecular weight heparin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Pregnant women with antiphospholipid antibody syndrome

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
Live birth rate in both arms of the trial (defined as the live birth rate after 24 weeks gestation).	—

Secondary

Measure	Time frame
The secondary outcome measures will concern maternal morbidity, e.g. osteoporosis, and fetal parameters, such as premature delivery and the incidence for "small for dates".	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026